Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK INHIBITION IN PRECLINICAL ARTHRITIS
DRKS00032648Phase 2Recruiting
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Oct 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib 4 mg/day with Placebo (2 arms). Started Oct 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on DRKS00032648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00032648.